Iradimed Corporation (NASDAQ:IRMD) Short Interest Up 18.2% in December

Iradimed Corporation (NASDAQ:IRMD) saw a significant growth in short interest in December. As of December 31st, there was short interest totalling 124,100 shares, a growth of 18.2% from the December 15th total of 105,000 shares. Based on an average trading volume of 39,400 shares, the short-interest ratio is presently 3.1 days. Currently, 1.6% of the company’s stock are sold short.

Insider Activity at Iradimed

In related news, CFO John Glenn sold 2,500 shares of the firm’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $54.18, for a total transaction of $135,450.00. Following the completion of the sale, the chief financial officer now owns 4,383 shares of the company’s stock, valued at $237,470.94. This trade represents a 36.32 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 37.10% of the stock is owned by insiders.

Institutional Investors Weigh In On Iradimed

Large investors have recently added to or reduced their stakes in the stock. Charles Schwab Investment Management Inc. grew its position in Iradimed by 189.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 66,632 shares of the medical equipment provider’s stock worth $3,351,000 after purchasing an additional 43,635 shares during the period. Eagle Asset Management Inc. bought a new stake in Iradimed in the 3rd quarter worth approximately $1,239,000. Allspring Global Investments Holdings LLC boosted its stake in shares of Iradimed by 14.4% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 20,122 shares of the medical equipment provider’s stock worth $1,012,000 after acquiring an additional 2,538 shares during the last quarter. Barclays PLC boosted its stake in shares of Iradimed by 113.9% during the 3rd quarter. Barclays PLC now owns 23,774 shares of the medical equipment provider’s stock worth $1,196,000 after acquiring an additional 12,657 shares during the last quarter. Finally, Albert D Mason Inc. purchased a new position in shares of Iradimed during the 3rd quarter worth $737,000. Institutional investors own 92.34% of the company’s stock.

Iradimed Trading Up 1.4 %

NASDAQ:IRMD traded up $0.81 during trading hours on Friday, reaching $59.17. The company had a trading volume of 50,168 shares, compared to its average volume of 37,022. Iradimed has a 52 week low of $40.18 and a 52 week high of $59.31. The firm has a market cap of $749.68 million, a price-to-earnings ratio of 40.53 and a beta of 0.81. The firm’s 50 day moving average price is $54.76 and its 200-day moving average price is $50.17.

Iradimed Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, November 25th. Shareholders of record on Friday, November 15th were given a $0.15 dividend. This represents a $0.60 dividend on an annualized basis and a yield of 1.01%. The ex-dividend date was Friday, November 15th. Iradimed’s dividend payout ratio (DPR) is presently 41.10%.

About Iradimed

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.